Long-term post-mortem studies following neurturin gene therapy in patients with advanced Parkinson’s disease

Extended Treatment with Glial Cell Line-Derived Neurotrophic Factor in Parkinson’s Disease

(2019) Alan L. Whone et al.   Journal of Parkinsons Disease

Randomized trial of intermittent intraputamenal glial cell line-derived neurotrophic factor in Parkinson’s disease

(2019) Alan Whone et al.   BRAIN

Temporal evolution of microglia and α-synuclein accumulation following foetal grafting in Parkinson’s disease

(2019) C Warren Olanow et al.   BRAIN

Trial of magnetic resonance–guided putaminal gene therapy for advanced Parkinson's disease

(2019) John D. Heiss et al.   MOVEMENT DISORDERS

Do subjects with minimal motor features have prodromal Parkinson disease?

(2018) Yaping Chu et al.   ANNALS OF NEUROLOGY

Structure and biophysical characterization of the human full-length neurturin–GFRa2 complex: A role for heparan sulfate in signaling

(2018) Jenny Sandmark et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Glycomic and Proteomic changes in aging brain nigrostriatal pathway

(2018) Rekha Raghunathan et al.   MOLECULAR & CELLULAR PROTEOMICS

Neurotrophic factors hold promise for the future of Parkinson’s disease treatment: is there a light at the end of the tunnel?

(2018) Ava Nasrolahi et al.   REVIEWS IN THE NEUROSCIENCES

Silencing Alpha Synuclein in Mature Nigral Neurons Results in Rapid Neuroinflammation and Subsequent Toxicity

(2018) Matthew J. Benskey et al.   Frontiers in Molecular Neuroscience

Clinical tests of neurotrophic factors for human neurodegenerative diseases, part 2: Where do we stand and where must we go next?

(2017) Raymond T. Bartus et al.   NEUROBIOLOGY OF DISEASE

Rationally Engineered AAV Capsids Improve Transduction and Volumetric Spread in the CNS

(2017) Nicholas M. Kanaan et al.   Molecular Therapy-Nucleic Acids

Impact of age and vector construct on striatal and nigral transgene expression

(2016) Nicole K Polinski et al.   Molecular Therapy-Methods & Clinical Development

Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial

(2015) C. Warren Olanow et al.   ANNALS OF NEUROLOGY

Nurr1 and Retinoid X Receptor Ligands Stimulate Ret Signaling in Dopamine Neurons and Can Alleviate  -Synuclein Disrupted Gene Expression

(2015) N. Volakakis et al.   JOURNAL OF NEUROSCIENCE

Trophic factors for Parkinson's disease: To live or let die

(2015) C. Warren Olanow et al.   MOVEMENT DISORDERS

Post-mortem assessment of the short and long-term effects of the trophic factor neurturin in patients with α-synucleinopathies

(2015) R.T. Bartus et al.   NEUROBIOLOGY OF DISEASE

Disease duration and the integrity of the nigrostriatal system in Parkinson’s disease

(2013) Jeffrey H. Kordower et al.   BRAIN

Enhanced neurotrophic distribution, cell signaling and neuroprotection following substantia nigral versus striatal delivery of AAV2-NRTN (CERE-120)

(2013) Christopher D. Herzog et al.   NEUROBIOLOGY OF DISEASE

Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients

(2013) R. T. Bartus et al.   NEUROLOGY

Alterations in axonal transport motor proteins in sporadic and experimental Parkinson’s disease

(2012) Yaping Chu et al.   BRAIN

GDNF fails to exert neuroprotection in a rat  -synuclein model of Parkinson's disease

(2011) M. Decressac et al.   BRAIN

Heparan sulfate proteoglycan syndecan-3 is a novel receptor for GDNF, neurturin, and artemin

(2011) Maxim M. Bespalov et al.   JOURNAL OF CELL BIOLOGY

Novel mutations at RET ligand genes preventing receptor activation are associated to Hirschsprung’s disease

(2011) Macarena Ruiz-Ferrer et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: Support for nigral targeting in Parkinson's disease

(2011) Raymond T. Bartus et al.   NEUROBIOLOGY OF DISEASE

Gene transfer provides a practical means for safe, long-term, targeted delivery of biologically active neurotrophic factor proteins for neurodegenerative diseases

(2011) Christopher D. Herzog et al.   Drug Delivery and Translational Research

Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial

(2010) William J Marks et al.   LANCET NEUROLOGY

Bioactivity of AAV2-neurturin gene therapy (CERE-120): Differences between Parkinson's disease and nonhuman primate brains

(2010) Raymond T. Bartus et al.   MOVEMENT DISORDERS

Striatal Readministration of rAAV Vectors Reveals an Immune Response Against AAV2 Capsids That Can Be Circumvented

(2009) Carmen S Peden et al.   MOLECULAR THERAPY

Neurturin-Mediated Ret Activation Is Required for Retinal Function

(2008) M. A. Brantley et al.   JOURNAL OF NEUROSCIENCE

Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2–neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial

(2008) William J Marks et al.   LANCET NEUROLOGY